Results 211 to 220 of about 334,593 (294)

Integrative profiling of lactylation reveals prognostic biomarkers and an immunosuppressive niche in acute myeloid leukemia. [PDF]

Front Immunol
Guo Z, Zhang W, Gao Z, Li Q, Guo D, Yue L, Liu Y, Ni X, Fan S, Hai X.   +9 more
europepmc   +1 more source

Impact of CD34+ cell dose on outcomes of related allogeneic PBSCT in adult AML patients

British Journal of Haematology, EarlyView.
Summary CD34+ cell dose is believed to impact the outcomes of allogeneic peripheral blood stem cell transplantation (PBSCT), yet the optimal dose remains unclear. We retrospectively reviewed 2407 adult patients with acute myeloid leukaemia who underwent their first related PBSCT between 2000 and 2019.
Yusuke Toda, Tomoyasu Jo, Yasuyuki Arai, Kaito Harada, Masamitsu Yanada, Takahiro Fukuda, Satoshi Yoshihara, Noriko Doki, Naoyuki Uchida, Yasuo Mori, Yuta Hasegawa, Yukio Kondo, Toshiro Kawakita, Tetsuya Eto, Tetsuya Nishida, Masatsugu Tanaka, Makoto Onizuka, Katsuhiro Shono, Masayuki Hino, Tatsuo Ichinohe, Yoshiko Atsuta, Takaaki Konuma   +21 more
wiley   +1 more source

Latviešu Ārstu un Zobārstu Apvienības goda biedra profesora Dr. med. Jēkaba Alkšņa dzīves gaita

Acta Medico-Historica Rigensia, 1999
AML Medicīnas vēstures institūts
doaj   +1 more source

Glycolytic Enzymes Are Part of an Oncogenic Network in AML. [PDF]

Cells
Nagel S, Meyer C, Pommerenke C.
europepmc   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy. [PDF]

Blood Lymphat Cancer
Zhang J, Jiang Q, Liu T, Li H, Liang Y, Lu X, Pang H, Li S, Li Y, Zhang R.   +9 more
europepmc   +1 more source

Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia. [PDF]

Clin Exp Med
Gao J, Wang F, Chen Y, Wu P, Jia Y, Song X.   +5 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. [PDF]

J Clin Med
Stafylidis C, Diamantopoulos PT.
europepmc   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source